Aboytes MCA, Morales FMG, Torres FJ, Torres VA

Idioma: Español
Referencias bibliográficas: 35
Paginas: 8-16
Archivo PDF: 160.98 Kb.

RESUMEN

Introducción: El objetivo fue el de establecer la asociación entre el síndrome metabólico (SM) y sus componentes, con la parálisis facial idiopática (PFI).
Métodos: Diseño de casos y controles. Se incluyeron casos con PFI de menos de seis meses de evolución. Los controles fueron pareados por sexo y edad. Se usaron los criterios del ATPIII para el diagnóstico de SM. Se calculó razón de momios (RM) mediante análisis de regresión logística.
Resultados Hubo diferencias entre los 51 casos y los 100 controles en glucemia, concentración sérica de triglicéridos y presión arterial diastólica. La hipertrigliceridemia, hiperglucemia, hipertensión arterial y obesidad abdominal estuvieron asociadas de forma independiente y significativa con la parálisis facial con una RM de 2.57 (IC 95%: 1.26-5.22), 2.32 (IC 95%: 1.01-5.36), 2.09 (IC 95%: 1.05-4.16) y 2.06 (IC 95%: 1.03-4.11).
Conclusiones: Componentes del síndrome metabólico son factores de riesgo para PFI.

REFERENCIAS (EN ESTE ARTÍCULO)

1. De Diego JJ. Primm MP. Gavilán J. Etiopatogenia de la parálisis facial periférica idiopática o de Bell. Rev Neurol 2001; 32: 1055-1059.

2. Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanahigara N. Bell palsy and Herpes Simples Virus: identification of viral DNA in endoneurial fluid and muscle. Ann Internal Med 1996; 124: 27- 30.

3. Linder T, Bossart W, Bodmer D. Bell’s palsy and Herpes Simplex Virus: fact or mystery? Otol Neurotol 2005; 26: 109-113.

4. Lazarini PR. Ferreira-Vianna M. Alves-Alcantara MP. Scalia RA. Caiaffa Filho HH. Herpes Simpex Virus in the saliva of peripheral Bell’s palsy patients. Rev Bras Otorrinolaringol 2006; 72: 7-11.

5. Abiko Y, Ikeda M, Hondo R. Secretion and dynamics of Herpes Simplex Virus in tears and saliva of patients with Bell’s palsy. Otol Neurotol 2002; 23 :779-783.

6. Montes-Dorantes G, Vales-Hidalgo O, Pane-Pianese C, Rembao-Bojórquez D. Determinación de virus del herpes simple tipo I en pacientes con parálisis facial periférica idiopática y respuesta al tratamiento con antivirales y esteroides. Arch Neurocienc 2002; 7: 76-82.

7. Volk GF, Klingner C, Finkenspier M, Witte OW, Guntinas-Lichius O. Prognostication of recovery time after acute facial palsy: a prospective cohort study. BMJ open 2013; 3: e003007.

8. Sullivan FM, Swan IRC, Donnan PT, Morrison JM, Smith BH, McKinstry B. et al. Early treatment with prednisolone or acyclovir in Bell’s palsy. N Engl J Med 2007; 357: 1598-1607.

9. De Almeida JR, Al Khabori M, Guyatt GH, Witterick IJ, Lin VYW, Nedzelski JM, Chen JM. Combined corticosteroid and antiviral treatment for Bell Palsy. JAMA 2009; 302: 985-993.

10. Kanoh N, Nomura J, Satomi F. Nocturnal onset and development of Bell’s palsy. Laryngoscope 2005; 115: 99-100.

11. Shmorgun D, Chan W, Ray JG. Association between Bell’s palsy and pre-eclampsia. QJM 2002; 95: 359-362.

12. Campbell K, Brundage JF. Effects of climate, latitude and season on the incidence of Bell’s palsy in the US Armed Forces, October 1997 to September 1999. Am J Epidemiol 2002; 156: 32-39.

13. Aditya V. LMN facial palsy in pregnancy: An opportunity to predict preeclampsia – Report review. Case Reports in Obstetrics and Gynecology 2014; 2014: 626871.

14. Barden A, Singh R, Walters B, Richie J, Roberman B, Beilin L. Factors predisponing to pre-eclampsia in women with gestational diabetes. J Hypertens 2004; 22: 2371-2378.

15. Wolf M, Hubel C, Lam C, Sampson M, Ecker J, Ness R, Rajakumar A, Daftary A, Shakir AS, Seely EW, Roberts JM, Sukhatme VP, Karumanchi SA, Thandhani R. Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab 2004; 89: 6239-6243.

16. Kaur J. A comprehensive review on metabolic syndrome. Cardiology Research and Practice 2014; 2014: 943162.

17. Freeman D, Norrie J, Caslake M, Gaw A, Ford I, Lowe GDO, O’Reilly DSJ, Packard CJ, Sattar N. West Scotland Coronary Prevention Study Groupo. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600.

18. Devaraj S, Xu D, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003; 107: 398-404.

19. Chen J, Wildman R, Hamm L, Muntner P, Reynolds K, Whelton P, He J. Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2960-2965.

20. Dell’Omo G, Penno G, Pucci L, Pellegrini G, Scotti A, Prato S, Pedrinelli R. The vascular effects of doxazosin in hypertension complicated by metabolic syndrome. Coron Artery Dis 2005; 16: 67-73.

21. Fassbender K, Bertsch T, Mielke O, Muhlhauser F, Hennerici M. Adhesion molecules in cerebrovascular diseases: evidence for inflammatory endothelial activation in cerebral large- and small-vessel disease. Stroke 1999; 30: 1647-1650. doi:10.11601/01.STR8196430.8.1647

22. Lazman M. Davis EF. Lewandowski AJ. Worton SA. Kenworthy Y. Kelly B. Leeson P. Prevention of vascular dysfunction after preeclampsia: a potential long term outcome measure and emerging goal of treatment. J Pregnancy 2012; 2012: 704146.

23. Aboytes-Meléndez CA. Torres-Valenzuela A. Estudio epidemiológico de parálisis facial en el Centro de Rehabilitación y Educación Especial (C.R.E.E.) Durango. Reporte preliminar. La salud en Durango 2004; 5:19-23.

24. Grundy S. Brewer HB. Cleeman J. Smith S. Lenfant C. Definition of the metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004; 109: 433-438.

25. Chobanian A. Bakris G. Black H. Cushmann W. Green L. Izzo J, Jones DW. Materson BJ. Oparil S. Wright JT. Roccella EJ. Seventh report of the Joint National Commitee on Prevention, Detection, Evaluation, and Treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.

26. Ford ES. Giles WH. Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey JAMA 2002; 287: 356-359.

27. Gómez-Pérez FJ. Ríos Torres JM. Aguilar-Salinas CA. Lerman-Garber I. Rull JA: Posición de la SMNE sobre el manejo del síndrome metabólico. Segunda parte. Revista de Endocrinología y Nutrición 2005; 13: 9-23.

28. Wacher-Rodarte N. II. Epidemiología del síndrome metabólico. Gac Med México 2009; 145: 384- 391.

29. Mueanchoo P. Tepparak N. Kongkamol C. Soonthornpun S. Sathirapanya P. The prevalence of metabolic syndrome in nondiabetic patients with a previous history of Bell’s palsy. Health 2012; 4(4), Article ID: 18848.

30. Hughes RAC. Umapathi T. Gray A. Gregson NA. Noori M. Panala AS. ét. ál. A controlled investigation of the cause of chronic idiopathic axonal polyneuropathy. Brain 2004; 127: 1723-1730.

31. Visser NA. Vrancken AFJE. Van Der Schouw YT. Van Der Berg LH. Notermans NC. Chronic idiopathic axonal neuropathy is associated with metabolic syndrome. Diabetes care 2013; 36: 817-822.

32. Balci K, Utku U. Carpal tunnel syndrome and metabolic syndrome. Acta Neurol Scand 2007; 116: 113-117

33. Kassem HS, Azar ST, Zanfout MS, Sawaya RA. Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients. Neuro Endocrinol Lett 2005; 26: 775-779.

34. Schulz JB. Lindenau J. Seyfried J. Dihgans J. Gluthatione, oxidative stress an neurodegeneration. Eur J Biochem 2000; 267: 4904-4911.

35. Ferrer-Viant D. Jorge-Fonseca C. Cutino-Claves I. García-Rodríguez RE, Arce-Gómez DL. Radicales libres y su papel en la homeostasia neuronal. MEDISAN 1999; 3: 5-11.